Biomedical literature, made navigable
Discover articles through diseases, drugs, treatments, interventions, clinical instruments, institutions and funders extracted from the BMJ open corpus.
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsChoose an entity to see the articles in which it was identified.
… and multifactorial, involving mechanisms such as hypertension, coronary artery disease, left ventricular dysfunction, right ventricular impairment, sy…
…opposed to 18/37 (49%) of FAPI-positive patients.Conclusions In psoriasis patients with arthralgia, 68Ga-FAPI uptake, indicating fibrobla…
…ims Combination therapy with endoscopic band ligation (EBL) and propranolol (PPL) is the standard approach for secondary prevention of oeso…
…Background and Importance Cladribine is an immunosuppressive drug used in relapsing–remitting multip…
…18%), meropenem (16.8%), and metronidazole (12.4%), followed by ceftriaxone (9.1%).In 2024, 44 meetings were held, reviewing 185 treatments…
…12 (10–60) 4.5 (0–80) 7.5 (0–10) 0 (0–10) 8.5 (3–10) 3.5 (0–10) Baricitinib 22 (21–40) 1 (0–18) 16 (5–40) 1 (0–10) 6 (0–1) 0 (0–1) 8 (0–5) …
…to pruritus and sleep outcomes compared with those treated with tralokinumab.Conflict of Interest No conflict of interest…
…specially with drugs that have narrow therapeutic range such as sodium valproate, thus requiring therapeutic drug monitoring. On the other hand,…
…78.7%), followed by semaglutide (69.6%), exenatide (49.6%), and liraglutide (39.6%).Cox regression analysis (reference: dulaglutide) showed…
…-lowering agents (ezetimibe 4.1%, PCSK9 inhibitor 0.4%, none on bempedoic acid).Conclusions Notable gaps exist in statin prescribing and LDL g…
…nalysis of the phase 3 PHILA trial confirmed the superiority of pyrotinib in combination with trastuzumab and docetaxel over placebo in c…
… a retrospective cross-sectional study. Patients diagnosed with AECOPD through pulmonary function tests and hospitalised in People’s H…